Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma

Matthew J. Rabinowitz; Taylor P. Kohn; Vanessa N. Peña; Iryna V. Samarska; Andres Matoso; Amin S. Herati

doi:10.1016/j.eucr.2020.101488

Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma

Matthew J. Rabinowitz, Taylor P. Kohn, Vanessa N. Peña, Iryna V. Samarska, Andres Matoso, Amin S. Herati

School of Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Azoospermia is classified as the complete absence of sperm in ejaculate and accounts for 10–15% of male infertility. Many anticancer drugs are known to cause defects in spermatogenesis, but the effects of immune checkpoint inhibitor cancer therapy on spermatogenesis remains largely unknown. Presented here is a normozoospermic man (60 million sperm/cc of ejaculate) who received a trial combination treatment of Ipilimumab/Nivolumab to treat BRAF negative, stage IV metastatic melanoma. Two years after the treatment, the patient presented as completely azoospermic. The patient subsequently underwent microdissection testicular sperm extraction, during which no sperm was retrieved, and sertoli-only pathology was elucidated.

Original language	English (US)
Article number	101488
Journal	Urology Case Reports
Volume	34
DOIs	https://doi.org/10.1016/j.eucr.2020.101488
State	Published - Jan 2021

Keywords

Azoospermia
BRAF
Immunotherapy
Infertility
Male
immune Checkpoint inhibitor therapy

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eucr.2020.101488

Cite this

@article{657b3e0eca924c5aaf397e1219f5fc7d,

title = "Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma",

abstract = "Azoospermia is classified as the complete absence of sperm in ejaculate and accounts for 10–15% of male infertility. Many anticancer drugs are known to cause defects in spermatogenesis, but the effects of immune checkpoint inhibitor cancer therapy on spermatogenesis remains largely unknown. Presented here is a normozoospermic man (60 million sperm/cc of ejaculate) who received a trial combination treatment of Ipilimumab/Nivolumab to treat BRAF negative, stage IV metastatic melanoma. Two years after the treatment, the patient presented as completely azoospermic. The patient subsequently underwent microdissection testicular sperm extraction, during which no sperm was retrieved, and sertoli-only pathology was elucidated.",

keywords = "Azoospermia, BRAF, Immunotherapy, Infertility, Male, immune Checkpoint inhibitor therapy",

author = "Rabinowitz, {Matthew J.} and Kohn, {Taylor P.} and Pe{\~n}a, {Vanessa N.} and Samarska, {Iryna V.} and Andres Matoso and Herati, {Amin S.}",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2021",

month = jan,

doi = "10.1016/j.eucr.2020.101488",

language = "English (US)",

volume = "34",

journal = "Urology Case Reports",

issn = "2214-4420",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma

AU - Rabinowitz, Matthew J.

AU - Kohn, Taylor P.

AU - Peña, Vanessa N.

AU - Samarska, Iryna V.

AU - Matoso, Andres

AU - Herati, Amin S.

PY - 2021/1

Y1 - 2021/1

N2 - Azoospermia is classified as the complete absence of sperm in ejaculate and accounts for 10–15% of male infertility. Many anticancer drugs are known to cause defects in spermatogenesis, but the effects of immune checkpoint inhibitor cancer therapy on spermatogenesis remains largely unknown. Presented here is a normozoospermic man (60 million sperm/cc of ejaculate) who received a trial combination treatment of Ipilimumab/Nivolumab to treat BRAF negative, stage IV metastatic melanoma. Two years after the treatment, the patient presented as completely azoospermic. The patient subsequently underwent microdissection testicular sperm extraction, during which no sperm was retrieved, and sertoli-only pathology was elucidated.

AB - Azoospermia is classified as the complete absence of sperm in ejaculate and accounts for 10–15% of male infertility. Many anticancer drugs are known to cause defects in spermatogenesis, but the effects of immune checkpoint inhibitor cancer therapy on spermatogenesis remains largely unknown. Presented here is a normozoospermic man (60 million sperm/cc of ejaculate) who received a trial combination treatment of Ipilimumab/Nivolumab to treat BRAF negative, stage IV metastatic melanoma. Two years after the treatment, the patient presented as completely azoospermic. The patient subsequently underwent microdissection testicular sperm extraction, during which no sperm was retrieved, and sertoli-only pathology was elucidated.

KW - Azoospermia

KW - BRAF

KW - Immunotherapy

KW - Infertility

KW - Male

KW - immune Checkpoint inhibitor therapy

UR - http://www.scopus.com/inward/record.url?scp=85097393479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097393479&partnerID=8YFLogxK

U2 - 10.1016/j.eucr.2020.101488

DO - 10.1016/j.eucr.2020.101488

M3 - Article

C2 - 33299797

AN - SCOPUS:85097393479

SN - 2214-4420

VL - 34

JO - Urology Case Reports

JF - Urology Case Reports

M1 - 101488

ER -

Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this